Skip to main content

Genotyping for HPV types 16, 18/45

Cervical adenocarcinoma rates have been increasing for decades2

Aptima HPV mRNA assay genotyping includes genotype 45 to identify almost all HPV types associated with cervical adenocarcinoma. Evidence shows that the addition of HPV type 45 identifies more women at risk for adenocarcinoma with minimal impact to colposcopy rates.1

HPV type 45:

  • is only prevalent in 0.4% of women with normal cytology1
  • is the third most common HPV type in invasive cervical cancer; associated with 12% of adenocarcinomas1

Types 16, 18/45 show higher carcinogenic potential relative to all other high-risk HPV types.3


Aptima, along with Pap testing, has a combined sensitivity of over 99% for detecting cancer and high-grade cervical disease.4


With better specificity than HPV DNA testing, Aptima has been shown to reduce false positives and minimize unnecessary invasive procedures.4


For more information

To set up testing, contact your sales representative or call 1.866.MYQUEST (1.866.697.8378).

You can also learn more about Aptima in our Test Directory.

Test Directory

The Aptima HPV assay detects E6/E7 viral mRNA from 14 high-risk types of human papillomavirus in cervical specimens (in ThinPrep® Pap Test vials containing PreservCyt® Solution and collected with broomtype or cytobrush/spatula devices). The test is indicated to screen women ≥21 years with ASCUS cytology to determine the need for colposcopy, and to screen women ≥30 years for high-risk HPV types. This information with cytology history, other risk factors, and guidelines may be used to manage patients. See for more details.

The assay is not a substitute for regular cervical cytology screening. The results of this test are not intended to prevent women from proceeding to colposcopy. The assay has not been evaluated for managing HPV vaccinated women, women with prior ablative or excisional therapy, hysterectomy, who are pregnant, or have other risk factors. Aptima and other associated logos are registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States, and/or other countries.



  1. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1045-1056.
  2. Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Woman’s Health. 2012;21(10):1031-1037.
  3. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349-2359.
  4. Aptima HPV assay [package insert].

Co-testing solutions for

cervical cancer

Learn more about how Pap and HPV mRNA

testing work together to provide early

detection of cervical cancer.

Download Brochure